Evidence map›Paper›PMID 36005135›Full record

ArticleCurrent issues in molecular biology2022

Liraglutide Exerts Protective Effects by Downregulation of

Tea Omanovic Kolaric, Tomislav Kizivat, Vjera Mihaljevic, Milorad Zjalic, Ines Bilic-Curcic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, George Y Wu, Martina Smolic

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tea Omanovic KolaricDepartment of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.ORCID 0000-0001-6338-4070
Tomislav KizivatDepartment of Nuclear Medicine and Oncology, Faculty of Medicine Osijek, J. Huttlera 4, 31000 Osijek, Croatia.ORCID 0000-0002-2523-6007
Vjera MihaljevicDepartment of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.
Milorad ZjalicDepartment of Molecular Medicine and Biotechnology, Faculty of Medicine Rijeka, B. Branchetta 20, 51000 Rijeka, Croatia.ORCID 0000-0003-4076-2942
Ines Bilic-CurcicDepartment of Pharmacology, Faculty of Medicine Osijek, J. Huttlera 4, 31000 Osijek, Croatia.ORCID 0000-0002-8861-5987
Lucija KunaDepartment of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.
Robert SmolicDepartment of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.
Aleksandar VcevDepartment of Pathophysiology and Physiology with Immunology, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.
George Y WuDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, 135 Dowling Way, Farmington, CT 06030, USA.
Martina SmolicDepartment of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Crkvena 21, 31000 Osijek, Croatia.

Funding

Croatian Ministry of Science, Education and Sports dedicated to multi-year institutional funding of scientific activity at the Josip Juraj Strossmayer University of Osijek IP10-Mefos-2019 (to Martina Smolic)Croatian Ministry of Science, Education and Sports dedicated to multi-year institutional funding of scientific activity at the Josip Juraj Strossmayer University of Osijek IP15-Mefos-2021 (to Martina Smolic)Croatian Ministry of Science, Education and Sports dedicated to multi-year institutional funding of scientific activity at the Josip Juraj Strossmayer University of Osijek IP8-FDMZ-2021 (to Robert Smolic)
6 · The paper itself

Abstract

(1) Background: With the aging of the population and polypharmacy encountered in the elderly, drug-induced steatosis (DIS) has become frequent cause of non-alcoholic steatosis (NAS). Indeed, NAS and DIS may co-exist, making the ability to distinguish between the entities ever more important. The aim of our study was to study cell culture models of NAS and DIS and determine the effects of liraglutide (LIRA) in those models. (2) Methods: Huh7 cells were treated with oleic acid (OA), or amiodarone (AMD) to establish models of NAS and DIS, respectively. Cells were treated with LIRA and cell viability was assessed by MTT, lipid accumulation by Oil-Red-O staining and triglyceride assay, and intracellular signals involved in hepatosteatosis were quantitated by RT-PCR. (3) Results: After exposure to various OA and AMD concentrations, those that achieved 80% of cells viabilities were used in further experiments to establish NAS and DIS models using 0.5 mM OA and 20 µM AMD, respectively. In both models, LIRA increased cell viability (p < 0.01). Lipid accumulation was increased in both models, with microsteatotic pattern in DIS, and macrosteatotic pattern in NAS which corresponds to greater triglyceride accumulation in latter. LIRA ameliorated these changes (p < 0.001), and downregulated expression of lipogenic ACSL1, PPARγ, and SREBP-1c pathways in the liver (p < 0.01) (4) Conclusions: LIRA ameliorates hepatocyte steatosis in Huh7 cell culture models of NAS and DIS.

Indexed as

amiodaroneHuh7 cell lineliraglutideNAS

Identifiers

PMID36005135
PMCPMC9406665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.